Therapeutic Advances in Medical Oncology

《肿瘤学治疗进展》(TAM)是一份经过同行评审的开放获取期刊，专注于癌症医学治疗方面的开拓性努力和创新研究。该杂志是出版伦理委员会(COPE)的成员之一。医学肿瘤学的治疗进展提供了最高质量的同行评审的原始研究文章、评论和学术评论，对癌症医学治疗的开创性努力和创新性研究。该杂志具有很强的临床和药理学焦点，旨在吸引临床和医学肿瘤学研究人员的国际观众，为该领域的最新研究和观点的快速传播提供在线论坛。编辑们欢迎所有肿瘤学领域的原创研究文章。该杂志主要发表原创研究文章和评论文章。原始研究手稿可能包括实验室、动物或人类/临床研究——所有阶段。给编辑的信和案例报告也将被考虑。审查文章包括专家意见/观点审查（包括单药和药物类审查）、叙述性审查和治疗领域审查。系统综述、荟萃分析、邮戳和健康经济和药物经济评论也受到欢迎。应遵循适当的赤道网络报告指南（如随机对照试验联合会和系统回顾/荟萃分析Prisma）。该杂志赞同ICMje的要求，即临床试验应在首次患者登记时或之前在世卫组织批准的公共试验登记处登记。但是，与所有试验活动一致，如果可以接受延迟注册的理由，将考虑回顾性注册试验。该杂志坚持一个盲目的审查过程，在这个过程中，审查者的名字通常不会透露给作者，除非审查者要求公开他们的身份。手稿由至少两名评审人进行评审；第一次编辑决定通常在提交后3周内作出，在线第一次出版通常在接受后3周内作出。

Therapeutic Advances in Medical Oncology (TAM) is a peer-reviewed open access journal which focuses on pioneering efforts and innovative studies in the medical treatment of cancer. The journal is a member of the Committee on Publication Ethics (COPE).Therapeutic Advances in Medical Oncology delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in medical oncology, providing an online forum for rapid dissemination of recent research and perspectives in this area.The editors welcome original research articles across all areas of oncology.The journal publishes original research articles and review articles primarily. Original research manuscripts may include laboratory, animal or human/clinical studies – all phases. Letters to the Editor and Case Reports will also be considered.Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). The journal endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable.The journal adheres to a blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees; a first editorial decision is generally reached within 3 weeks of submission and Online First publication is usually within 3 weeks of Acceptance.